(News Bulletin 247) – Roche unveiled on Wednesday the provisional results of a phase III study evaluating tiragolumab in combination with Tecentriq in patients with non-small cell lung cancer.
The biopharmaceutical group explains that it has resigned itself to presenting these results following the “inadvertent disclosure” of the first conclusions of the trial.
In a press release, the group points out that the data collected as part of the study was not yet “fully developed” at the time of this unexpected revelation, even if the results revealed today seem rather encouraging.
This second interim analysis indeed shows a median overall survival of 22.9 months in treated patients, compared to 16.7 months in the Tecentriq group alone, an element that seems promising knowing that it is the endpoint main of the test.
Following these announcements, Roche shares jumped 3.9% on Wednesday morning on the Zurich Stock Exchange, marking by far the largest increase in the SMI index.
Roche specifies that the study is continuing while waiting to have sufficient data to establish a final analysis of the survival of the 534 patients followed.
The study, dubbed ‘Skyscraper-01’, focuses on metastatic non-small cell lung cancer with high PD-L1 expression.
Tiragolumab is a new cancer immunotherapy designed to bind to the TIGIT immune inhibitory receptor considered a ‘breakthrough therapy’ by health authorities.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
